BHLHB3 is a basic helix-loop-helix (bHLH) domaincontaining protein that acts as a transcriptional repressor. We found that BHLHB3 transcript levels were low in three human lung cancer cell lines and downregulated in human lung adenocarcinomas as compared to normal lung tissue. BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. The reduced colony growth was likely due to inhibition of cell proliferation as suggested by the downregulation of cyclin D1 (CCND1) expression in NCI-H520 cells transfected to overexpress the BHLHB3 gene; no evidence of apoptosis was observed. These results point to the potential role of the BHLHB3 protein as a tumor suppressor for lung cancer.
BHLHB3 is a basic helix-loop-helix (bHLH) domaincontaining protein that acts as a transcriptional repressor. We found that BHLHB3 transcript levels were low in three human lung cancer cell lines and downregulated in human lung adenocarcinomas as compared to normal lung tissue. BHLHB3 gene overexpression inhibited colony formation of A549, NCI-H520 and NCI-H596 lung cancer cells. The reduced colony growth was likely due to inhibition of cell proliferation as suggested by the downregulation of cyclin D1 (CCND1) expression in NCI-H520 cells transfected to overexpress the BHLHB3 gene; no evidence of apoptosis was observed. These results point to the potential role of the BHLHB3 protein as a tumor suppressor for lung cancer. The basic helix-loop-helix (bHLH) proteins form heterodimers or homodimers via their HLH domains and bind to DNA through a region of basic amino acids immediately N terminal to the HLH dimerization domain (Davis and Turner, 2001 ). The bHLH transcription factors are involved in coordinated regulation of gene expression and cell differentiation in most mammalian tissues (Honma et al., 2002) , affecting neurogenesis, vasculogenesis, mesoderm segmentation, myogenesis and T lymphocyte development (Davis and Turner, 2001) . bHLH are targets of the Notch signaling pathway (Davis and Turner, 2001; Iso et al., 2003) , which can be dysregulated in a variety of human neoplasms (Davis and Turner, 2001; Allenspach et al., 2002) . Proteins encoded by the Class B bHLH protein 3 (BHLHB3: also known as DEC2, SHARP-1) gene and its homolog Class B bHLH protein 2 (BHLHB2: also known as DEC1, STRA13, SHARP-2) share 42% total sequence identity and 97% identity in the bHLH region (Fujimoto et al., 2001) . Both genes encode bHLH transcriptional repressors involved in the regulation of the mammalian molecular clock (Honma et al., 2002) . Retroviral insertional mutagenesis analysis has implicated the mouse Bhlhb3 gene in the development of mouse leukemia/lymphoma (Suzuki et al., 2002) . Indeed, in two cases of leukemia/lymphoma, the retrovirus integration disrupted the gene coding sequence (Suzuki et al., 2002) (http://genome2.ncifcrf.gov/RTCGD), suggesting that Bhlhb3 loss of function is required for leukemia/lymphoma development. No information is currently available on the role of Bhlhb3 in other tumor types in mice. However, on the basis of our previous report suggesting an association between the BHLHB3-Ala298Val polymorphism and survival of lung adenocarcinoma (ADCA) patients (Falvella et al., 2006) , we tested BHLHB3 for its putative tumor suppressor activity in human lung cancer.
BHLHB3 transcript levels in human lung cancer cell lines were B100-(A549, NCI-H596) to B1000-fold (NCI-H520) lower than those in a pool of 20 RNA samples of human normal lung tissue, as determined by kinetic reverse transcriptase-PCR. Analysis of BHLHB3 gene expression in 18 pairs of matched normal tumor lung tissue obtained from lung ADCA patients revealed downregulation of the gene in nine tumors (range: 2-to 11-folds) and upregulation in five tumors (range: 2-to 3.5-folds); four pairs were excluded from the analysis since BHLHB3 expression was undetectable in either normal or tumor tissue. Overall, there was a slight downregulation of BHLHB3 expression in lung ADCA as compared to normal lung tissue, but the difference was not statistically significant ( Figure 1, top panel) . We also measured BHLHB2 mRNA levels in our matched samples; all 14 pairs had detectable levels of BHLHB2 mRNA and the gene was overexpressed in 2 tumor samples, downregulated in 11 tumors and unchanged in 1 pair ( Figure 1 , bottom panel; P ¼ 0.01, Kruskal-Wallis test). The finding of downregulated BHLHB2 expression in lung cancer contrasts with that of (Li et al., 2003) , who reported a slight upregulation of BHLHB2 (DEC1) expression in lung cancer in a small series (n ¼ 4) of lung cancer/ normal lung tissue pairs (Li et al., 2003) . In addition, we found a direct correlation between BHLHB3 and BHLHB2 transcript levels (Spearman's r ¼ 0.508; P ¼ 0.006), whereas (Li et al., 2003) described an inverse relationship between BHLHB3 and BHLHB2 expression. On the basis of a previous study indicating repression of mouse Bhlhb2 promoter activity by Bhlhb3 transfection in mouse fibroblast cell line 10T1/2 (Azmi et al., 2003) , we tested the hypothesis that BHLHB3 directly affects mRNA levels of BHLHB2. Measurement of BHLHB2 mRNA levels in NCI-H520 lung cancer cells stably transfected to overexpress BHLHB3 (see Figure 1 legend for details of kinetic reverse transcriptase) revealed only a slight decrease (0.56±0.10-fold, mean±s.e., n ¼ 12) as compared to vector-transfected cells, arguing against any significant, if any, direct modulation of BHLHB2 expression by BHLHB3 and instead, suggesting that the observed correlation between BHLHB2 and BHLHB3 expression in the normal lung and lung ADCA tissues rests in common transcription regulation. The discrepancy between the experiments carried out in mice and our findings may rest in the differences in the cell lines or species analysed.
To analyse the potential functional role of BHLHB3 in human lung cancer, we assessed the clonogenicity of human lung cancer cell lines A549, NCI-H520 and NCI-H596, which expressed low levels of BHLHB3 mRNA compared to normal lung tissue, after transfection with mammalian expression vectors containing full-length BHLHB3 cDNAs corresponding to either the Ala298 or Val298 variant (Figure 2a) . We also transfected a nonlung cancer cell line (HepG2) expressing B1000-fold lower levels of BHLHB3 transcript than in normal lung tissue. Clonogenic activity decreased B3-(A549) to B15-fold (NCI-H520, NCI-H596) in the BHLHB3-overexpressing lung cancer cells (Po0.0001), with no significant difference between the two variants (Figures 2b and c) . HepG2 transfectants showed no difference from controls in clonogenic activity, which was uniformly high in both cases (not shown).
To determine whether the decreased clonogenic activity of BHLHB3-transfected NCI-H520 cells might reflect induction of apoptosis, NCI-H520 cells were transiently transfected and analysed after 48 and 72 h by indirect immunofluorescence assay in live cells using the Annexin V-FITC kit (Bender MedSystems, Vienna, Austria); no evidence of apoptosis was obtained at either time point (data not shown). As an additional assay of apoptosis, we used an anti-PARP antibody (Cell Signaling Tech Inc., Danvers, MA, USA) by western blot in stable transfected cells; again, we found no evidence of PARP protein cleavage (not shown). Instead, quantitative PCR of NCI-H520 cells stably transfected to overexpress BHLHB3 (Figure 3 ) and using cyclin D1 as a marker of proliferation (Berthet and Kaldis, 2007 ) revealed a decrease (0.25 ± 0.04-fold, n ¼ 8) of cyclin D1 mRNA expression (measured using Hs00277039_m1 (CCND1) TaqMan Gene Expression Assays; Applied Biosystems, Foster City, CA, USA) in BHLHB3-transfected versus vector-transfected cells, consistent with western blot analysis ( Figure 3 ) and with a previous study (Azmi et al., 2004) showing that BHLHB3 overexpression in mouse myoblast cell line C2C12 promotes cell cycle exit in association with decreased levels of cyclin D1 protein expression. Indeed, inhibition of cyclin D1 protein expression is associated with cell cycle arrest in cancer cell lines (Berthet and Kaldis, 2007) .
BHLHB3 has been reported to suppress transcription of the CYP7A gene in a hepatocarcinoma cell line (Noshiro et al., 2004) . Consistent with that study, Figure 1 mRNA expression levels in normal and tumor lung tissue of lung adenocarcinoma (ADCA) patients. Lung ADCA surgical specimens and corresponding normal lung tissue were obtained from pathologically documented patients enrolled at Istituto Nazionale Tumori, Milan, Italy. Total RNAs were extracted with RNeasy Midi kit (Qiagen, Valencia, CA, USA). cDNAs were reverse transcribed using oligo(dT) primers and ThermoScript RT-PCR System (Invitrogen, Carlsbad, CA, USA). mRNA levels were assayed by kinetic reverse transcriptase-PCR using Hs00229146_m1 (BHLHB3) and Hs00186419_m1 (BHLHB2) TaqMan Gene Expression Assays (Applied Biosystems). The real-time PCR amplification mixture contained cDNA template diluted in RNase-free water, 10 ml 2X TaqMan Universal PCR Master Mix No AmpErase UNG and 1 ml of 20X TaqMan Gene Expression Assay Mix (Applied Biosystems). Reactions were run in duplicate on the 7900HT System (Applied Biosystems) for 40 cycles (95 1C for 15 s, 60 1C for 1 min) after enzyme activation (95 1C for 10 min). The human hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene (Hs99999909_m1 TaqMan Gene Expression Assays, Applied Biosystems) was used as control for possible differences in cDNA amounts. Values were calculated using the comparative Ct method, and relative expression levels are directly proportional to the ÀDCt values. kRT-PCRs for BHLHB3 (top) or BHLHB2 (bottom) were carried out in 14 paired normal and tumor samples. The line within each box represents the median ÀDCt value; upper and lower edges of each box represent the seventy-fifth and twenty-fifth percentile, respectively; upper and lower bars indicate the highest and lowest values determined, respectively.
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HepG2 cells transfected with a luciferase construct containing the 5 0 flanking region of rat CYP7A, an expression plasmid containing the rat D site of the albumin promoter (albumin D-box) binding protein (DBP) to enhance transcriptional activity of the CYP7A promoter, a mammalian expression vector containing full-length BHLHB3 cDNA (Val or Ala variant), and an internal control plasmid showed a B5-fold reduction in luciferase activity (Po0.0001) as compared to controls (Figure 4) , indicating the suppression of DBP-induced CYP7A promoter activity by BHLHB3. This suppression was also apparent in similarly transfected A549 cells, although DBP-induced expression levels were lower and the reduction in luciferase activity was slight (1.4-to 1.7-fold; Po0.01) as compared to those in HepG2 cells (Figure 4) . No significant differences (ANOVA and Sheffe's test) between the two nonsynonymous alleles (Ala298Val) of the BHLHB3 gene were observed in the suppression of CYP7A transcriptional activity in either HepG2 or A549 cells. Transrepression of CYP7A Figure 2 Colony formation in human lung cancer cell transfectants. Human cell lines A549, NCI-H520 and NCI-H596 (American Type Culture Collection, Rockville, MD, USA), derived from lung carcinoma, lung squamous cell carcinoma and lung adenosquamous carcinoma, respectively, were used for in vitro functional assays. The BHLHB3 gene coding region was amplified from the cDNA clone isolated from a full-length human lung plasmid cDNA library (OriGene Technologies, Rockville, MD, USA; Val variant) or from lung tissue (Ala variant) using primers 5 0 -agaacatggacgaaggaatt-3 0 and 5 0 -gggagcttcctttcctgg-3 0 . PCR aliquots were subcloned in the pEF6/V5-His-TOPO vector (Invitrogen) in-frame with the V5 epitope and polyhistidine tag. Clones were screened and sequenced using vector-specific primers. (a) Immunodetection of recombinant BHLHB3 variant proteins in transfected A549, NCI-H520 and NCI-H596 cells using anti-V5 antibody (Invitrogen). Cells were transfected using FuGENE HD Transfection Reagent (Roche Applied Science, Basel, Switzerland). Nuclear proteins were extracted with CelLytic NuCLEAR Extraction Kit (Sigma, St Louis, MO, USA). Equal amounts of protein were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto Hybond-C nitrocellulose membranes (GE Healthcare Life Sciences, Buckinghamshire, UK) and immunoblotted with anti-V5 (Invitrogen). The ECL Plus Western Blotting Detection System (GE Healthcare Life Sciences) was used for detection. Lane 1, Ala variant, lane 2, Val variant, lane 3, empty vector. (b) Inhibition of in vitro colony formation in BHLHB3-transfected human lung carcinoma A549, NCI-H520 and NCI-H596 cells. Cell lines were transfected with recombinant or control empty vector (pEF6/V5-His) using SuperFect Transfection Reagent (Qiagen) (A549 and NCI-H596) or Effectene Transfection Reagent (Qiagen) (NCI-H520). Transfected clones were selected with 5 mg ml À1 (A549) or 2 mg ml À1 (NCI-H520 and NCI-H596) blasticidin (Invitrogen) for 2 weeks, methanol-fixed and stained with 10% Giemsa. (c) Numbers (mean ± s.e.) of Giemsa-stained colonies produced by empty vector (empty bars) or BHLHB3-transfected cells. Colonies were automatically counted with either Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA) (NCI-H520 or NCI-H596 cells) or ImageQuant TL software (GE Healthcare Life Sciences) (A549 cells). All experiments were carried out in sextuplicate (Ala298, diagonalfilled bars; Val298, black-filled bars; asterisk, Po0.0001). activity was instead not observed in NCI-H520 and NCI-H596 cells (not shown). These results indicate that transrepression of the CYP7A promoter and inhibition of clonogenic activity by BHLHB3 are not correlated, since BHLHB3 was an efficient transrepression factor in HepG2 cells but did not inhibit colony formation in these cells and, on the contrary, BHLHB3 did not affect transrepression of CYP7A activity in NCI-H520 and NCI-H596 cells but strongly inhibited their clonogenic activity. The possibility that BHLHB3 transrepression activity relevant to tumor suppression is associated with another as yet uncharacterized promoter(s) or is mediated by cell-type-specific factors remains to be examined.
Our results point to a possible tumor suppressor role of BHLHB3 in lung cancer, with no apparent difference between the Ala298Val variants. Such activity may be mediated by cyclin D1 downregulation. 
